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PREVALENCE OF IgG VARICELLA ZOSTER VIRUS ANTIBODIES IN THE KUIKURO
AND KAIABI INDIGENOUS COMMUNITIES IN XINGU NATIONAL PARK, BRAZIL,
BEFORE VARICELLA VACCINATION
Manuel Mindlin LAFER, Maria Isabel DE MORAES-PINTO & Lily Yin WECKX
SUMMARY
 The purpose of the study was to estimate the prevalence of IgG antibodies against varicella zoster virus (VZV) in the two most
populated indigenous ethnic groups from Xingu Indigenous National Park, in Brazil, prior to the introduction of vaccination
against the disease, and to determine the positive and the negative predictive values of a history of varicella infection. In 2001, 589
inhabitants of two Kuikuro villages and three Kaiabi villages were evaluated and provided information concerning previous
varicella infection. An indirect immunosorbent assay (ELISA) to detect IgG anti-VZV antibodies was performed in 224 blood
samples - volunteer selection had no interference of anamnesis. IgG prevalence was 80.8% (95% Confidence Interval: 76% -
86%). The seroepidemiology of varicella in Xingu National Park prior to varicella vaccine introduction was comparable to the
Brazilian national seroprevalence described in the literature, and so were the positive (98%) and the negative predictive value
(41%) of the referred history.
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INTRODUCTION
Varicella is a very contagious and vaccine preventable disease,
occurring mostly during childhood, as a consequence of primary
infection of varicella zoster virus (VZV)2,8,13. Although it usually
presents a benign course, it may cause complications, especially in
high risk individuals2-3,8,13. Morbidity and mortality due to varicella
are significantly higher in adults13.
Studies on seroprevalence in tropical countries demonstrate a
greater proportion of adolescents and adults susceptible to varicella,
and with higher risk of complications, when compared with those of
temperate countries2,13. In these countries, indirect immunosorbent
assay (ELISA) used to detect IgG VZV antibodies have demonstrated
prevalence equal to or higher than 90%1,9,16,21,27,30-31. In Brazil, general
surveys have shown a seroprevalence of 85.4%10 and 94.2%26, closer
to the pattern observed in temperate countries.
Nowadays, the Brazilian Indigenous population is 350,000
inhabitants from 218 different ethnic groups distributed in 554
discontiguous territories, occupying 12% of the National territory6,18,20.
In 2000, an outbreak of varicella occurred in 94.6% of 278 Araweté
Indians, in the state of Pará, with 3% death (personnal communication).
At Xingu National Park, a neighboring area, there was a varicella
outbreak in 1999, reaching 5.8% of the inhabitants, 20% of whom
were over 15 years of age. Seven patients (3.2%) presented severe
forms of the disease (personal communication).
In view of that, Brazilian Ministry of Health decided to vaccinate the
Native Indian population. The present study was undertaken to estimate
the seroepidemiology of varicella at Xingu National Park immediately
before the vaccine was introduced. That allowed us to compare the results
in the Indian population with national ones. We have also calculated the
positive predictive value of the previous history of varicella infection in
order to assess whether that information would identify potential candidates
for vaccination in Brazilian Indian population.
MATERIAL AND METHODS
The study was performed between June and September 2001 at
Xingu National Park, located North of the State of Mato Grosso, Brazil,
encompassing an area of 2,642,003 hectares, where 14 ethnic groups
live. The most populated of the indigenous ethnic groups are the
Kuikuro, living in the Upper Xingu region, south of the Park, and the
Kaiabi, living in the Lower Xingu region, north of the Park12,19. Kuikuro
Indians are autochthonous, their settling records going back to a period
between 200 B.C.and 800 A.D.15. On the other hand, the Kaiabi
population of the Park migrated after 1949, most of them after 196114.
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Selection of visited communities was done together with the
Council of Indigenous Leaders, acknowledged by the Health Ministry12.
Written consent was obtained by the Park leaders, the community chiefs
and the indigenous health agents.
The population of Xingu National Park at the time was 3919
inhabitants (personal communication). Three Kaiabi communities were
visited (“Capivara”, “Guarujá” and “Tuiararé”) in Lower Xingu, and
two Kuikuro communities (“Afukuri” and “Kuikuro”) in Upper Xingu,
amounting to 589 individuals (94.5% of the population of these
communities).
All subjects were questioned regarding previous history of varicella
infection; the answers were preferably given by individuals, but they
were also given by relatives or indigenous health agents. Of note, this
survey was carried out prior to the introduction of varicella vaccine.
Two hundred and twenty four blood samples were collected (38%
of the individuals of the survey) through recruitment method, at each
home, without interference of the answer given to anamnesis, and
following the same age distribution of the population of the Park. We
restrained our selection to one in two individuals under 20 years of age
and one in four individuals over 20 years of age, as determined by the
aforementioned Council.
After blood sample collection, serum was obtained, kept at 2 oC to
8 oC and sent to the Research Laboratory of the Division Pediatric
Infectious Diseases of the Federal University of São Paulo. There it
was kept at -20 oC until analysis. An in house indirect immunosorbent
assay was performed to detect IgG VZV antibodies24,28. Because an
internationally accepted antibody level that predicts previous contact
with wild varicella zoster virus or vaccine is not available, we have
established a cutoff based on antibody values assessed on sera from 12
month-old infants without evidence of previous VZV infection. Twenty-
two children who had been regularly followed up from birth and did
not have evidence of previous varicella infection assessed both by
clinical examination and repeated serologic testing during the first year
of life were tested for varicella antibodies at 12 months of age. Cutoff
value of 0.2 IU/mL was calculated by adding mean antibody levels
(0.04 IU/mL) to three standard deviations (3 x 0.04 IU/mL)24.
Statistical analysis was performed using Microsoft Excel® 2000,
EPI INFO release 6, and SPSS release 10.0. Probabilities were assessed
for 95% significance. Chi-square test and Fisher’s exact test were used;
Dunnett’s test was used for non-comparable variance analysis, and
Fleiss’ test11 was used to obtain confidence interval of near 100%
seroprevalences.
RESULTS
The prevalence of VZV antibodies in the whole sample was 80.8%
[95% Confidence Interval (CI): 76% - 86%]. The prevalence in the
different age groups is summarized in Table 1. We observe a continuous
increment in seropositivity up to the 11 to 15 year age group. From that
age on, only one 20-year-old woman presented a negative VZV serology.
Table 2 shows sample distribution and the percentage of seropositive
individuals in each village. As confidence intervals suggest, seroposi-
tivity in Afukuri (Upper Xingu), Kuikuro (Upper Xingu) and Guarujá
(Lower Xingu) communities were comparable (Chi-square test, p =
0.1595). Seropositivities in Capivara and Tuiararé communities (both
in Lower Xingu) were also comparable (Fisher’s exact test, p = 0.5915).
Comparison between the first group of three communities and the
second one with two communities demonstrated a different
seropositivity (Chi-square test, p < 0.001).
Previous history of varicella infection had a 98% positive predictive
value (lower 95% CI: 95%), and a 41% negative predictive value (as
derived from Table 3). No differences were noticed between males
and females (Chi-square test, p = 0.94). Positive predictive value of
the previous varicella history was 100% in subjects at the age of one to
five years old, 94% in subjects at the age of six and 10 years old, and
100% in the group with subjects at the age of 11 or over.
Table 1
Seropositivity for varicella zoster virus in different age groups of Brazilian
indigenous communities from Xingu National Park
Samples
Age Group N Seropositivity Percentage 95% Confidence
(years) Interval
< 1 4 1 25 0 - 67
1 to 5 64 37 57.8 46 - 70
6 to 10 57 45 78.9 68 - 89
11 to 15 38 38 100 91 - 100
16 to 20 35 34 97.1 85 - 100
21 or + 26 26 100 87 - 100
Total 224 181 80.8 76 - 86
Table 3
Varicella zoster virus serology according to previous history of varicella in
indigenous communities from Xingu National Park
Anamnesis VZV Serology
(Previous Varicella) Positive Negative Total
Yes 121 2 123
No 60 41 101
Total 181 43 224
Table 2
Distribution of the sample population and seropositivity for varicella zoster
virus according to the community of Brazilian indigenous people of Xingu
National Park
Samples
Community N Seropositivity Percentage 95% Confidence
Interval
Afukuri 38 23 60.5 45 - 76%
Kuikuro 94 72 76.6 68 - 85%
Capivara 29 29 100 88 - 100%
Guarujá 21 16 76.2 58 - 94%
Tuiararé 42 41 97.6 87 - 100%
Total 224 181 80.8 76 - 86%
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DISCUSSION
In Brazil, varicella is popularly known as catapora, rather than
varicella (or chickenpox), which means irrupted fire in Tupi language17,
the “general language” in which indigenous people from different tribes
used to communicate in Brazil. This is an evidence of the knowledge
Brazilian indigenous groups have of the disease.
Prevalence of varicella was statistically comparable to that observed
in a national study on seroprevalence, where a 85.5% prevalence was
calculated in 3653 individuals between one and 40 years of age10.
Varicella seropositivity in the Xingu population (57.1%), and Brazilian
population (57.6%) between one and five years of age was comparable
(Chi-square test, p = 0.9685). They were also comparable among six
and 10 years old (78.9% in Xingu and 85.5% in Brazil; Chi-square
test, p = 0.179) and among 16 and 20 years old (97.1% in Xingu, and
95.5% in Brazil; Fisher’s exact test, p = 0.53). In the population among
11 and 15 years old, two-tailed Fisher’s exact test did not show any
difference (p = 0.06): thus, the prevalence is also high in this age group
in Xingu National Park, 100% (CI 95% 91% - 100%), as in the country,
91% (CI 95% 88.7% - 93.2%).
Before this study, prevalence of varicella among indigenous people
was evaluated in only one epidemiological study with the Tiriyo, who
live in the north of Para State, in the border with Suriname. That was
in the second half of the sixties, and the study demonstrated 80.4% of
immunity in a sample of 51 individuals4-5.
We could not explain the difference in prevalence found in the two
groups of villages, Upper (Afukuri and Kuikuro) and Lower (Capivara,
Guarujá and Tuiararé) Xingu (Table 2). However, the differences in
prevalence found in the study should not be attributed to internal
migration, the habit of establishing new communities, the marriages
among families of different communities or the changes in leaderships.
Negative predictive value of the history was 41% (Table 3), low
and unreliable, as reported in the literature30. By contrast, positive
predictive value of previous history of varicella in Xingu National Park
was high, 98%, and it could be an efficient and economic measure to
avoid vaccination, excluding from the “susceptible” category the
individuals who referred previous varicella.
Other studies in Brazil have demonstrated different positive
predictive values, ranging from 83.1% in an age group from five months
to 12 years29 to 90.9% in medical students and nurses7, 95.1% in patients
from one to 40 years10 and 100% in neonatal staff28. In view of that,
CLEMENS et al. suggested that report of previous disease should be
considered as a criterion to discard vaccination10.
The positive predictive value of a previous history of varicella is
higher on temperate clime countries, where seroprevalence tends to be
higher22. Previous studies, as this one, have shown that, for unknown
reasons, Brazil has a higher varicella seroprevalence than would be
expected for a tropical country22-23,25, and also a high positive predictive
value of previous history of varicella.
In sum, we have shown that the seroprevalence of VZV is high in
Brazilian Indigenous people, and comparable to the general prevalence
found in Brazil. Despite the cultural differences and the difficulties in
communication, the positive predictive value of a previous history of
varicella proved to be high, suggesting it is a reliable method to discard
vaccination.
RESUMO
Prevalência de anticorpos IgG contra o vírus varicela zoster nas
aldeias indígenas Kuikuro e Kaiabi do Parque Nacional do
Xingu, Brasil, antes da vacinação contra varicela
O objetivo do estudo foi aferir a prevalência de anticorpos IgG
contra o Vírus Varicela-Zoster (VVZ) nos dois grupos étnicos indígenas
mais povoados do Parque Nacional Indígena do Xingu, Brasil, antes
da introdução da vacinação contra a doença, e determinar os valores
preditivos positivo e negativo da história de infecção de varicela. Em
2001, 589 habitantes de duas aldeias Kuikuro e três aldeias Kaiabi
foram avaliados e forneceram dados referentes à infecção prévia por
varicela. Um ensaio imunoenzimático indireto (ELISA) foi realizado
em 224 amostras de sangue para detectar anticorpos IgG anti-VVZ - a
seleção de voluntários não teve interferência da anamnese. A
prevalência de IgG foi de 80,8% (Intervalo de Confiança de 95%: 76%
- 86%). A soroepidemiologia de varicela no Parque Nacional do Xingu
antes da introdução da vacina foi comparável à soroprevalência nacional
descrita na literatura, assim como os valores preditivos positivo (98%)
e negativo (41%) da história referida.
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